


Ask a doctor about a prescription for GARYDOL FORTE 5 mg/5 mg LOZENGES
Leaflet: information for the user
GARYDOL FORTE 5 mg / 5 mg lozenges
Chlorhexidine dihydrochloride / Benzocaine
Read the entire leaflet carefully before starting to use this medication, as it contains important information for you.
Follow exactly the administration instructions of the medication contained in this leaflet or as indicated by your doctor or pharmacist.
Contents of the leaflet:
The active ingredients of this medication, chlorhexidine and benzocaine, act by combining the antiseptic and disinfectant action of chlorhexidine with the local anesthetic action of benzocaine.
This medication is used for the symptomatic local and temporary relief of mild mouth and throat infections that occur with pain and without fever, such as throat irritation, hoarseness, and small mouth ulcers.
GARYDOL FORTE can be used in adults, adolescents, and children from 6 years of age.
You should consult a doctor if it worsens or does not improve after 2 days.
Do not takeGARYDOL FORTEif:
If you are allergic to chlorhexidine dihydrochloride, benzocaine, or any of the other components of this medication (listed in section 6).
Warnings and precautions
It is recommended to maintain good oral hygiene to reduce the accumulation of tartar and possible tooth discoloration that may be caused by chlorhexidine.
Consult your doctor or pharmacist before starting to take this medication.
Stop taking this medication and consult your doctor immediately if you or a child in your care develop pale, gray, or blue skin, lips, or nail edges, headache, dizziness, difficulty breathing, fatigue, and rapid heartbeat.
Due to the local anesthetic action of benzocaine, avoid eating or drinking immediately after taking a lozenge.
Use under adult supervision in small children and individuals with aspiration and swallowing problems, as lozenges are a potential choking hazard.
If symptoms persist or worsen, or if new symptoms appear, stop using this medication and consult your doctor.
Children
This medication should not be used in children under 6 years of age without consulting a doctor first. Children may be more sensitive to benzocaine.
Special populations:
The elderly and more debilitated patients may be more sensitive to benzocaine.
Other medications and GARYDOL FORTE
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Although not described in the recommended conditions of use, do not use with other mouth or throat medications without consulting your doctor or pharmacist.
This is especially important in the case of:
Anionic compounds and suspending agents (common components of toothpastes) reduce the effectiveness of chlorhexidine, so the mouth should be rinsed well after using toothpaste.
Taking GARYDOL FORTE with food and drinks
Avoid eating or drinking immediately after taking this medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Taking medications during pregnancy can be hazardous to the embryo, fetus, or breastfeeding child and should be monitored by your doctor.
If you are pregnant or breastfeeding, consult your doctor before using this medication.
Driving and using machines
It is unknown whether the combination of benzocaine and chlorhexidine has an effect on the ability to drive or operate machinery.
Interference with analytical tests:
If you are going to undergo any diagnostic test (including blood tests, urine tests, skin tests using allergens, etc.), inform your doctor that you are using this medication, as it may alter the results. This medication may interact with pancreatic function tests using bentiromide. Do not use this medication at least 3 days before the test and inform your doctor.
GARYDOL FORTE contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per lozenge; it is essentially "sodium-free".
Follow exactly the administration instructions of the medication contained in this leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
This medication is for buccopharyngeal use, so the lozenges should be dissolved slowly in the mouth without chewing or swallowing, as its action is local and only occurs when the product is in direct contact with the affected area.
The recommended dose is:
Adults, adolescents, and children from 6 years of age:
1 lozenge every 2 or 3 hours, if necessary, up to a maximum of 8 lozenges per day.
Dissolve slowly in the mouth without chewing or swallowing.
Always use the lowest effective dose.
If you notice that symptoms worsen or persist for more than 2 days after starting treatment or if fever, headache, nausea, or vomiting appear, you should consult your doctor as soon as possible.
If you take more GARYDOL FORTE than you should
Signs of overdose are: slurred speech, numbness, stumbling gait, blurred or double vision, dizziness, excitement or convulsions, ringing in the ears, increased sweating, decreased oxygen in the blood (pale, gray, or blue skin, lips, and nail edges, difficulty breathing, fatigue, confusion, headache, dizziness, and rapid heartbeat), and death in severe cases. It may also cause a decrease in blood pressure.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Side effects whose frequency has not been determined with precision are:
Tooth discoloration may occur. This pigmentation or discoloration can occur especially in people with tartar buildup. This alteration of tooth color is not permanent and can be removed by a dental cleaning.
The color of fillings may also be altered, in which case this discoloration can be permanent.
Alteration in taste perception may occur.
In some cases, GARYDOL FORTE may cause irritation in the mouth or irritation of the tip of the tongue or numbness of the tongue, which are usually transient, lack of sensitivity in the mouth, stomatitis (inflammation of the oral mucosa), desquamation of the mucosa, burning sensation in the mucosa, change in taste perception; tooth, tongue, filling, and denture discoloration; increased tartar, as well as hypersensitivity reactions such as urticaria, angioedema (swelling of certain skin areas), anaphylactic reaction, or anaphylactic shock, mainly due to chlorhexidine.
There have also been reports of parotid gland inflammation.
Some cases of methemoglobinemia caused by benzocaine have been reported, with symptoms such as difficulty breathing, cyanosis (bluish discoloration of the skin and mucous membranes), altered mental state, headache, fatigue, difficulty exercising, dizziness, and loss of consciousness.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of GARYDOL FORTE
Each lozenge contains:
Appearance of the product and package contents
GARYDOL FORTE are orange-flavored lozenges, white-yellowish in color, round, bisected, and scored on one side.
This medication is presented in packages of 20 lozenges, packaged in aluminum blister packs coated with PVDC and layered with PVC/PE/PVDC.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
Manufacturer:
Laboratorios Alcalá Farma, S.L.
Avenida de Madrid, 82
28802 Alcalá de Henares (Madrid)
Spain
Date of the last revision of this leaflet: September 2021
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for GARYDOL FORTE 5 mg/5 mg LOZENGES – subject to medical assessment and local rules.